Cell Rep Med. 2024 Aug 20. pii: S2666-3791(24)00379-3. [Epub ahead of print]5(8): 101665
Zhen Ding,
Guixing Ma,
Bo Zhou,
Siyuan Cheng,
Wanze Tang,
Yingying Han,
Litong Chen,
Wei Pang,
Yangshan Chen,
Dazhi Yang,
Huiling Cao.
Mesenchymal stromal cell (MSC) senescence is a key factor in skeletal aging, affecting the potential of MSC applications. Identifying targets to prevent MSC and skeletal senescence is crucial. Here, we report increased miR-29 expression in bone tissues of aged mice, osteoporotic patients, and senescent MSCs. Genetic overexpression of miR-29 in Prx1-positive MSCs significantly accelerates skeletal senescence, reducing cortical bone thickness and trabecular bone mass, while increasing femur cross-sectional area, bone marrow adiposity, p53, and senescence-associated secretory phenotype (SASP) levels. Mechanistically, miR-29 promotes senescence by upregulating p53 via targeting Kindlin-2 mRNA. miR-29 knockdown in BMSCs impedes skeletal senescence, enhances bone mass, and accelerates calvarial defect regeneration, also reducing lipopolysaccharide (LPS)-induced organ injuries and mortality. Thus, our findings underscore miR-29 as a promising therapeutic target for senescence-related skeletal diseases and acute inflammation-induced organ damage.
Keywords: Kindlin-2; MSC therapy; aging; bone; bone repair; miR-29; osteoporosis; p53; skeletal senescence